Physician profile
Anna Mikhailovsky
NPI 1003063488
$3,319.06
in general payments reported to CMS, 2019-2025
33 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $314 · 2021: $726 · 2022: $518 · 2023: $314 · 2024: $162 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $640.32 | 2020-2023 | |
| Abbvie INC. | $477.37 | 2019-2021 | |
| Novo Nordisk INC | $329.06 | 2021-2023 | Saxenda, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.99 | 2019 | |
| Glaxosmithkline, LLC. | $183.78 | 2019-2021 | |
| Nevro Corp. | $177.10 | 2023-2024 | Senza |
| Neurocrine Biosciences, INC. | $125.00 | 2019 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Sage Therapeutics, LLC | $116.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.15 | 2022 | |
| Radius Health, INC. | $72.53 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $71.29 | 2024-2025 | Dupixent |
| Endogastric Solutions, INC | $67.22 | 2023 | Esophyx |
| Abbott Laboratories | $61.79 | 2022-2023 | Freestyle Libre 2 |
| Amgen INC. | $50.70 | 2024-2025 | Repatha, Otezla, Evenity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.29 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $44.85 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Lilly USA, LLC | $42.81 | 2025 | Zepbound, Mounjaro |
| Insmed, INC. | $37.17 | 2025 | Arikayce |
| Organon LLC | $36.12 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $35.99 | 2019 | |
| Verrica Pharmaceuticals INC. | $26.41 | 2024 | Ycanth |
| Astellas Pharma US INC | $25.06 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $22.60 | 2019 | |
| Arbor Pharmaceuticals, INC. | $20.42 | 2021 | |
| Mannkind Corporation | $19.07 | 2022 | |
| Pfizer INC. | $17.79 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.67 | 2024 | Xifaxan |
| Dynavax Technologies Corporation | $16.50 | 2021 | |
| Boston Scientific Corporation | $15.27 | 2020 | |
| Merck Sharp & Dohme LLC | $13.83 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.15 | 2022 | |
| Sanofi Pasteur INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mikhailovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.